LLY News and Press, Eli Lilly and Company From 03/16/24

2024-03-16 09:15:00 ET When a company's big plans go awry, it's always worth reconsidering the merits of an investment. On March 8, regulators at the Food and Drug Administration (FDA) gave Eli Lilly (NYSE: LLY) an unwelcome surprise. Rather than granting approval to commercialize t...

2024-03-16 05:50:00 ET There's an old saying that "politics makes strange bedfellows." We could add that business sometimes does too. Pharmaceutical giant Eli Lilly (NYSE: LLY) and e-commerce/cloud services leader Amazon (NASDAQ: AMZN) might not seem to have much in comm...

2024-03-15 15:38:23 ET More on Eli Lilly Eli Lilly and Co (LLY) Cowen's 44th Annual Health Care Conference (Transcript) Eli Lilly: Will It Be The First Ever Trillion-Dollar Drug Company? Eli Lilly: Yes, It Is Too Late To Join The Party UBS sees Lilly GLP-1/sl...

2024-03-15 13:32:49 ET Summary Madrigal Pharmaceuticals has secured accelerated approval from the FDA for its drug Resmetirom, which treats nonalcoholic steatohepatitis (NASH), now known as metabolic dysfunction-associated steatohepatitis ("MASH"). The drug has received accelerate...

2024-03-15 09:29:14 ET Short interest in healthcare stocks moved higher from end of January to end of February, with bets against healthcare provider and services still being the most shorted sub-sector and Moderna jumping to be the most shorted company.... Read the full article on Se...

2024-03-15 09:15:00 ET Eli Lilly (NYSE: LLY) has a market capitalization of around $700 billion after soaring 130% over the past 12 months. Investors have become bullish on the company's long-term prospects, particularly with regulators recently approving Zepbound, a weight-loss dru...

2024-03-15 08:19:55 ET More on Madrigal Pharmaceuticals Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade) Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's...

2024-03-15 01:44:56 ET Summary I focus on dividend growth stocks as a strategy for long-term outperformance and financial freedom. I compare three new dividend-paying stocks (Meta Platforms, Booking Holdings, and Salesforce) to their high-conviction dividend growth stocks. I e...

2024-03-14 19:23:16 ET More on Terns Pharmaceuticals Seeking Alpha’s Quant Rating on Terns Pharmaceuticals Historical earnings data for Terns Pharmaceuticals Financial information for Terns Pharmaceuticals Read the full article on Seeking Alpha ...

2024-03-14 15:45:17 ET More on Madrigal Pharmaceuticals Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade) Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's...